<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - 获取免费报告) 的股价在周五的交易中突破了其 50 日移动平均线，此次上涨是由于其财报超出预期。该股的 50 日移动平均价为 15.52 美元，最高交易价达到 15.80 美元。Corvus Pharmaceuticals 的股票最后交易价为 15.55 美元，成交量为 980,529 股。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>2026 年这三只快速增长的股票的势头刚刚开始</li>
</ul>
<p>该公司报告本季度每股收益为（$0.15），低于市场共识预期的（$0.14），差距为（$0.01）。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 CRVS 进行了评估。华尔街 Zen 在 4 月 25 日的报告中将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。巴克莱在 1 月 20 日的研究报告中将 Corvus Pharmaceuticals 的目标价从 16.00 美元上调至 28.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 4 月 29 日的研究报告中将 Corvus Pharmaceuticals 的评级从 “卖出（e+）” 上调至 “卖出（d-）”。Cantor Fitzgerald 在 3 月 13 日的报告中重申了对 Corvus Pharmaceuticals 的 “增持” 评级。最后，HC Wainwright 在 1 月 20 日的研究报告中将 Corvus Pharmaceuticals 的目标价从 11.00 美元上调至 27.00 美元，并给予该公司 “买入” 评级。七位股票研究分析师对该股给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “适度买入”，平均目标价为 33.33 美元。</p>
<p><strong>获取我们对 Corvus Pharmaceuticals 的最新分析</strong></p>
<h2>机构投资者对 Corvus Pharmaceuticals 的看法</h2>
<p>几家对冲基金和其他机构投资者最近买入和卖出了 CRVS 的股票。GSA Capital Partners LLP 在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 25.9%。GSA Capital Partners LLP 目前拥有 401,407 股该公司的股票，价值 2,958,000 美元，此前在上个季度购买了额外的 82,675 股。NEOS Investment Management LLC 在第三季度收购了价值约 436,000 美元的 Corvus Pharmaceuticals 新股份。SEB Asset Management AB 在第一季度收购了价值约 3,319,000 美元的 Corvus Pharmaceuticals 新股份。肯塔基州教师退休系统在第一季度购买了价值约 117,000 美元的 Corvus Pharmaceuticals 新股份。最后，SG Americas Securities LLC 在第一季度将其在 Corvus Pharmaceuticals 的持股增加了 76.9%。SG Americas Securities LLC 目前拥有 35,420 股该公司的股票，价值 518,000 美元，此前在上个季度购买了额外的 15,399 股。46.64% 的股票目前由机构投资者持有。</p>
<h2>Corvus Pharmaceuticals 的价格表现</h2>
<p>该公司的市值为 13.1 亿美元，市盈率为 -29.90，贝塔值为 0.94。该公司有一个 50 日简单移动平均价为 15.52 美元，200 日简单移动平均价为 12.83 美元。</p>
<h2>关于 Corvus Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Corvus Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于下一代免疫肿瘤治疗的发现和开发。该公司的研究工作集中在利用先天和适应性免疫系统来对抗肿瘤驱动的免疫抑制。通过针对调节免疫细胞功能的关键通路，Corvus 旨在创造新型药物，这些药物可以与现有的癌症治疗相结合，以改善患者的治疗效果。</p>
<p>Corvus 的主要研发候选药物包括旨在抑制腺苷通路的小分子和抗体疗法，这是一种已知的肿瘤免疫逃逸介质。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Corvus Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Corvus制药

标普全球医疗股指数 ETF - iShares

医药突破 ETF - ALPS

<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS）股价超过其 50 日移动平均线 15.52 美元，目前交易价格为 15.55 美元，此前发布的财报令人失望，每股收益（EPS）为（0.15 美元），比预期低 0.01 美元。分析师的看法不一，其中七位给予 “买入” 评级，一位给予 “卖出” 评级。巴克莱将其目标价从 16.00 美元上调至 28.00 美元，而 HC Wainwright 则设定了 27.00 美元的新目标。机构投资者持有该股票的 46.64%，其市值为 13.1 亿美元，市盈率为-29.90</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday following a better than expected earnings announcement. The stock has a 50-day moving average of $15.52 and traded as high as $15.80. Corvus Pharmaceuticals shares last traded at $15.55, with a volume of 980,529 shares traded.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - 获取免费报告) 的股价在周五的交易中突破了其 50 日移动平均线，此次上涨是由于其财报超出预期。该股的 50 日移动平均价为 15.52 美元，最高交易价达到 15.80 美元。Corvus Pharmaceuticals 的股票最后交易价为 15.55 美元，成交量为 980,529 股。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年这三只快速增长的股票的势头刚刚开始</li>
</ul>
</div><p>The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01).</p>
<div class="lb-trans"><p>该公司报告本季度每股收益为（$0.15），低于市场共识预期的（$0.14），差距为（$0.01）。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms recently weighed in on CRVS. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 25th. Barclays raised their target price on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday, January 20th. Weiss Ratings raised shares of Corvus Pharmaceuticals from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Finally, HC Wainwright raised their price objective on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $33.33.</p>
<div class="lb-trans"><p>几家研究公司最近对 CRVS 进行了评估。华尔街 Zen 在 4 月 25 日的报告中将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。巴克莱在 1 月 20 日的研究报告中将 Corvus Pharmaceuticals 的目标价从 16.00 美元上调至 28.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 4 月 29 日的研究报告中将 Corvus Pharmaceuticals 的评级从 “卖出（e+）” 上调至 “卖出（d-）”。Cantor Fitzgerald 在 3 月 13 日的报告中重申了对 Corvus Pharmaceuticals 的 “增持” 评级。最后，HC Wainwright 在 1 月 20 日的研究报告中将 Corvus Pharmaceuticals 的目标价从 11.00 美元上调至 27.00 美元，并给予该公司 “买入” 评级。七位股票研究分析师对该股给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “适度买入”，平均目标价为 33.33 美元。</p>
</div><p><strong>Get Our Latest Analysis on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Corvus Pharmaceuticals 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Corvus Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of CRVS. GSA Capital Partners LLP grew its stake in shares of Corvus Pharmaceuticals by 25.9% in the 3rd quarter. GSA Capital Partners LLP now owns 401,407 shares of the company's stock worth $2,958,000 after purchasing an additional 82,675 shares during the last quarter. NEOS Investment Management LLC acquired a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $436,000. SEB Asset Management AB acquired a new stake in Corvus Pharmaceuticals during the first quarter valued at approximately $3,319,000. Teachers Retirement System of The State of Kentucky bought a new stake in Corvus Pharmaceuticals during the first quarter worth approximately $117,000. Finally, SG Americas Securities LLC grew its position in Corvus Pharmaceuticals by 76.9% in the first quarter. SG Americas Securities LLC now owns 35,420 shares of the company's stock worth $518,000 after buying an additional 15,399 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买入和卖出了 CRVS 的股票。GSA Capital Partners LLP 在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 25.9%。GSA Capital Partners LLP 目前拥有 401,407 股该公司的股票，价值 2,958,000 美元，此前在上个季度购买了额外的 82,675 股。NEOS Investment Management LLC 在第三季度收购了价值约 436,000 美元的 Corvus Pharmaceuticals 新股份。SEB Asset Management AB 在第一季度收购了价值约 3,319,000 美元的 Corvus Pharmaceuticals 新股份。肯塔基州教师退休系统在第一季度购买了价值约 117,000 美元的 Corvus Pharmaceuticals 新股份。最后，SG Americas Securities LLC 在第一季度将其在 Corvus Pharmaceuticals 的持股增加了 76.9%。SG Americas Securities LLC 目前拥有 35,420 股该公司的股票，价值 518,000 美元，此前在上个季度购买了额外的 15,399 股。46.64% 的股票目前由机构投资者持有。</p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的价格表现</h2>
</div><p>The company has a market cap of $1.31 billion, a P/E ratio of -29.90 and a beta of 0.94. The company has a fifty day simple moving average of $15.52 and a 200-day simple moving average of $12.83.</p>
<div class="lb-trans"><p>该公司的市值为 13.1 亿美元，市盈率为 -29.90，贝塔值为 0.94。该公司有一个 50 日简单移动平均价为 15.52 美元，200 日简单移动平均价为 12.83 美元。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于下一代免疫肿瘤治疗的发现和开发。该公司的研究工作集中在利用先天和适应性免疫系统来对抗肿瘤驱动的免疫抑制。通过针对调节免疫细胞功能的关键通路，Corvus 旨在创造新型药物，这些药物可以与现有的癌症治疗相结合，以改善患者的治疗效果。</p>
</div><p>Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.</p>
<div class="lb-trans"><p>Corvus 的主要研发候选药物包括旨在抑制腺苷通路的小分子和抗体疗法，这是一种已知的肿瘤免疫逃逸介质。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Corvus Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average  After Earnings Miss

Market Beat

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

医疗业 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

巴克莱银行

Corvus 制药（NASDAQ:CRVS）在收益未达预期后，股价突破了五十日移动平均线